GlassScriptPhysician profile
John Edward Blair
NPI 1023042744
$41,080.58
in general payments reported to CMS, 2019-2025
30 companies · $575 in 2025
The $575 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,646 · 2020: $2,374 · 2021: $13K · 2022: $14K · 2023: $7,119 · 2024: $1,322 · 2025: $575.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,757 · Travel and Lodging: $4,260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,757.48 |
| Travel and Lodging | $4,259.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $35,372.72 | 2019-2025 | Coroflow, Mitraclip, Pressurewire |
| Shockwave Medical, INC | $1,044.24 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Abiomed | $613.44 | 2019-2025 | |
| Medtronic, INC. | $586.12 | 2021-2024 | Mazor X System, Ffrangio |
| Inari Medical, INC. | $447.65 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Edwards Lifesciences Corporation | $424.17 | 2021-2024 | Sapien 3 Ultra Resilia |
| Boston Scientific Corporation | $331.52 | 2019-2025 | General - Atherectomy |
| Cardiovascular Systems INC. | $268.62 | 2021 | |
| Teleflex LLC | $195.38 | 2024 | Guideliner |
| Ancora Heart, INC. | $194.00 | 2023 | Accucinch |
| W. L. Gore & Associates, INC. | $192.57 | 2020 | |
| Biotronik INC. | $190.34 | 2019 | |
| Medtronic Vascular, INC. | $176.54 | 2019-2020 | |
| Cvrx, INC. | $171.32 | 2021 | |
| Penumbra, INC. | $142.66 | 2023 | Indigo System |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acist Medical Systems, INC. | $124.49 | 2021-2023 | |
| Philips North America LLC | $99.17 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $94.59 | 2021-2025 | Lifevest |
| Endotronix, INC. | $73.66 | 2023 | Cordella Pulomonary Artery Pressure Sensor |
| Amgen INC. | $73.00 | 2019-2022 | |
| Cardiva Medical, INC. | $58.61 | 2023 | Cardiva Vascade 6/7f Vcs, Cardiva Vascade 5f Vcs |
| Heartflow, INC. | $42.62 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $34.99 | 2021-2022 | |
| Ethicon US, LLC | $31.95 | 2025 | Stratafix, Dermabond Prineo |
| Astrazeneca Pharmaceuticals LP | $27.99 | 2020-2022 | |
| Terumo Medical Corporation | $24.57 | 2019 | |
| Pfizer INC. | $15.09 | 2022 | |
| Zoll Circulation INC | $14.85 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.71 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Edward Blair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.